全文获取类型
收费全文 | 522篇 |
免费 | 33篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 2篇 |
妇产科学 | 2篇 |
基础医学 | 103篇 |
口腔科学 | 7篇 |
临床医学 | 26篇 |
内科学 | 157篇 |
皮肤病学 | 6篇 |
神经病学 | 39篇 |
特种医学 | 14篇 |
外科学 | 37篇 |
综合类 | 10篇 |
预防医学 | 29篇 |
眼科学 | 47篇 |
药学 | 20篇 |
肿瘤学 | 38篇 |
出版年
2022年 | 3篇 |
2021年 | 10篇 |
2020年 | 10篇 |
2019年 | 4篇 |
2017年 | 4篇 |
2016年 | 3篇 |
2015年 | 9篇 |
2014年 | 7篇 |
2013年 | 10篇 |
2012年 | 25篇 |
2011年 | 21篇 |
2010年 | 18篇 |
2009年 | 18篇 |
2008年 | 22篇 |
2007年 | 30篇 |
2006年 | 16篇 |
2005年 | 20篇 |
2004年 | 27篇 |
2003年 | 20篇 |
2002年 | 25篇 |
2001年 | 23篇 |
2000年 | 36篇 |
1999年 | 38篇 |
1998年 | 5篇 |
1997年 | 5篇 |
1996年 | 6篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1992年 | 8篇 |
1991年 | 8篇 |
1990年 | 13篇 |
1989年 | 14篇 |
1988年 | 4篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1972年 | 4篇 |
1954年 | 2篇 |
1942年 | 2篇 |
1935年 | 2篇 |
1933年 | 2篇 |
1932年 | 2篇 |
1929年 | 2篇 |
1928年 | 2篇 |
1925年 | 4篇 |
排序方式: 共有555条查询结果,搜索用时 15 毫秒
1.
2.
Harder A Jendroska K Kreuz F Wirth T Schafranka C Karnatz N Théallier-Janko A Dreier J Lohan K Emmerich D Cervós-Navarro J Windl O Kretzschmar HA Nürnberg P Witkowski R 《American journal of medical genetics》1999,87(4):311-316
We present a novel large German kindred of fatal familial insomnia (FFI) consisting of three branches and comprising more than 800 individuals of 12 generations, the largest pedigree of any familial prion disease known today. There is a wide spectrum of clinical presentations leading to misdiagnoses of Olivo-Ponto-Cerebellar Atrophy (OPCA), Parkinson's or Alzheimer's disease in addition to Creutzfeldt-Jakob disease (CJD) and Gerstmann-Str?ussler-Scheinker (GSS) syndrome. Molecular genetic analysis of the prion protein gene (PRNP) confirmed the mutation D178N segregating with methionine at the polymorphic codon 129 of PRNP in all 7 patients examined. This polymorphism at codon 129 is supposed to discriminate between familial CJD (fCJD) and FFI; the 129M allele determines FFI and 129V fCJD. Furthermore, heterozygosity at this site appears to induce prolonged disease duration as compared to the homozygous condition. The variability of the clinical and pathological findings documented for our patients indicates the difficulty in establishing the diagnosis of FFI on clinical and on pathological grounds alone. In three cases (IX-97, XI-21, V-2) followed up by us prospectively insomnia was an early and severe symptom; however, in case notes analyzed retrospectively this symptom was frequently missed. In contrast to previous reports and in agreement with recent studies we cannot confirm a clear relationship between the status of the M/V polymorphism at codon 129 and the age-of-onset of this disease. 相似文献
3.
New monomers with sterically hindered free or blocked phenolic hydroxyl groups were used as starting compounds for the preparation of stable oxygen polyradicals. In this paper the synthesis of these monomers is described: 2,6-Di-(tert-butyl)-4-vinylphenol was obtained by decarboxylation of 3-[3,5-di-(tert-butyl)-4-hydroxyphenyl]acrylic acid in yields of 80–;90%. 2,6-Di-(tert-butyl)-4-isopropenylphenol was prepared from 3,5-di-(tert-butyl)-4-hydroxyphenyl methyl ketone and methyl iodide by a GRIGNARD reaction followed by the dehydration of 2-[3,5-di-(tert-butyl)-4-hydroxyphenyl]-2-propanol. 2,6-Di-(tert-butyl)-4-isopropenylphenyl methyl ether was obtained with 64% yield from 3,5-di-(tert-butyl)-4-methoxybenzonitrile by two consecutive GRIGNARD reactions with methyl iodide via the unknown compounds 3,5-di-(tert-butyl)-4-methoxyphenyl methyl ketone and 2-[3,5-di-(tert-butyl)-4-methoxyphenyl]-2-propanol, followed by dehydration of the tertiary alcohol with 89% phosphoric acid. 相似文献
4.
Robert M. Mader Harald Zilg Otto Schlappack Günther G. Steger Martina Baur Bertold Greifenberg Uwe Heberle Christian Dittrich 《Cancer chemotherapy and pharmacology》1995,37(1-2):91-96
Improved quality of life has gained importance over shortly lasting remissions in yet incurable metastatic breast cancer. Fractionation of drug administration is one of the possible approaches to reduce the concentration-dependent toxicity of anthracyclines. We evaluated the pharmacokinetics of 4-O-tetrahydropyranyladriamycin (THP-ADM) under weekly administration in patients with advanced breast cancer (dose escalation, from 20 to 27 mg/m2 THP-ADM). The concentration-time curves of THP-ADM in plasma were best described by an open three-compartment model [half-life of the first disposition phase (t1/2), 3.15 min; terminal elimination half-life (t
1/2), 13.9 h] with a mean area under the curve (AUC) of 12.2 ng h ml–1mg–1m–2, resulting in a mean plasma clearance of 86.91 h–1m–2. Metabolism included the formation of Adriamycin (ADM), Adriamycinol (ADM-OH), 13-dihydro-4-O-tetrahydropyranyladriamycin (THP-OH), 7-deoxyadriamycinone (7H-ADn), and 7-deoxy-13-dihydroadrimycinone (7H-ADn-OH), with maximal plasma concentrations ranging from 2.8 to 5.5 ng/ml. The mean total amount of cytotoxic anthracyclines excreted into urine, mainly as the parent drug, was 5% of the delivered dose. ADM and ADM-OH, but not the parent drug, were observed in urine at up to 4 weeks after the last therapeutic cycle. There was a significant correlation between the leukocyte nadir under therapy and the AUC of ADM-OH (r=0.800,P<0.05). Since no shift in the plasma kinetics was observed from the first to the sixth cycle, the favorable ratio of the AUCs of THP-ADM and ADM after fractionation of THP-ADM suggests lower toxic side effects attributable to ADM. This hypothesis was confirmed in a clinical study, where no severe cardiotoxicity and only mild alopecia were observed in 19 patients. Thus, pharmacokinetics studies might be helpful in both individualization of therapy with THP-ADM and optimization of the administration schedule. 相似文献
5.
A 17-year-old girl was found dead in a public toilet with fresh needle puncture marks. She was 18-20 weeks pregnant with a male fetus. Drug screening of her blood and urine indicated recent heroin use. Chronic drug use was confirmed by hair analysis. Amniotic fluid as well as fetal and maternal tissues and body fluids were analyzed by GC/MS and HPLC. All the fetal specimens were investigated, and the following levels of drugs were found: 6-monoacetyl-morphine (blood: 152 ng/g; amniotic fluid: 128 ng/g; brain: 140 ng/g; lung: 110 ng/g; liver: 2 ng/g; kidney: 40 ng/g), morphine (blood: 1360 ng/g; amniotic fluid: 604 ng/g; brain: 710 ng/g; lung: 1030 ng/g; liver: 2060 ng/g; kidney: 1100 ng/g), codeine (blood: 70 ng/g; brain: 60 ng/g; lung: 60 ng/g; liver: 90 ng/g; kidney: 70 ng/g), and morphine-3-glucuronide (amniotic fluid: 209 ng/g; brain: 170 ng/g; lung: 325 ng/g; kidney: 231 ng/g). Morphine-6-glucuronide was present in the maternal circulation but could not be detected in the fetal circulation. 相似文献
6.
7.
8.
Le Flem L Picard V Emmerich J Gandrille S Fiessinger JN Aiach M Alhenc-Gelas M 《Arteriosclerosis, thrombosis, and vascular biology》1999,19(4):1098-1104
The present study was designed to analyze the thrombomodulin proximal promoter region spanning nucleotides -293 to -12 to search for polymorphisms that could modify thrombomodulin gene expression in patients with venous thromboembolic disease. The study population comprised 205 patients and 394 healthy subjects of similar age and sex distribution. No polymorphisms and only 1 point mutation (G-33A) were found. The G-33A mutation was present at the heterozygous state in 2 patients and in 1 control. Being more frequent in the patients (0.97%) than in the controls (0.25%), the G-33A mutation might be a risk factor for venous thrombosis. To investigate the effect of this mutation on the thrombomodulin promoter activity, the proximal promoter region of the gene (bearing or not bearing the G-33A mutation) was inserted into a promotorless expression vector, upstream of the firefly luciferase gene, and transiently transfected into EA.hy926 endothelial cells. Under the conditions of the assay, the G-33A mutation mildly decreased the promoter activity. This study confirms that abnormalities of the thrombomodulin proximal promoter are not frequent in patients with venous thromboembolism. 相似文献
9.
Emmerich J 《La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne》2008,29(6):482-485
PURPOSE: Rare thrombophilic states are mostly associated with recurrent venous thrombosis or severe thrombosis such as neonatal purpura fulminans. We review here the various causes of rare thrombophilic states. CURRENT KNOWLEDGE AND KEY POINTS: Rare thrombophilic states associated with recurrent venous thrombosis include the following: antithrombin deficiencies, homozygous for protein C or protein S deficiency or compound heterozygous, double heterozygous for genetic thrombophilia and the rare thrombophilia due to auto-antibodies. Their frequency in patients with venous thromboembolism is below 2%. FUTURE PROSPECTS AND PROJECTS: These uncommon thrombophilic states require a treatment in a specialized department. 相似文献
10.
Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene 总被引:1,自引:0,他引:1
Picard V Bura A Emmerich J Alhenc-Gelas M Biron C Houbouyan-Reveillard LL Molho P Labatide-Alanore A Sié P Toulon P Verdy E Aiach M 《British journal of haematology》2000,110(3):731-734
We have investigated the molecular bases of familial antithrombin deficiency in eight French families. Eight mutations in the antithrombin coding exons were identified, seven of which were novel mutations. In all cases, individuals were heterozygous for the mutation. We found two small frameshift deletions in exon 3a, leading to type I deficiency. Five missense mutations in exons 3b or 5 also caused type I deficiency and their potential consequences on the antithrombin three-dimensional structure were analysed. The last mutation in exon 4 was associated with a type II 'reactive site' deficiency: a dysfunctional antithrombin that is affected in its interaction with thrombin was present in circulation. 相似文献